tbuckley/cabot-search huggingface dataset:
Efficacy and Safety of Unrelated Cord Blood Transplantation in Patients with Acquired Refractory Aplastic Anemia: A Phase II Study on Behalf of Eurocord and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy
Authors: Régis Peffault de Latour, Sylvie Chevret, Charlotte Jubert, Anne Sirvent, Claire Galambrun, Annalisa Ruggeri, Virginie Gandemer, Jérôme Cornillon, Fanny Rialland, Jean-Hugues Dalle, Noel Milpied, Benedicte Bruno, Catherine Paillard, Faezeh Legrand, Alexandra Salmon, Sabine Furst, Marie t Rubio, Jacques-Olivier Bay, Mohamad Mohty, Jerome Larghero, Eliane Gluckman, Gerard Socie
Journal: Blood (2016)
Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,
Authors: Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Paolo Neviani, Jason G Harb, Carolyn Paisie, Guido Marcucci, Sharon Shacham, Michael Kauffman, Danilo Perrotti
Journal: Blood (2011)
First Report of a Prospective Randomised Controlled Trial of Recombinant Human Erythropoietin after Allogeneic Blood Stem Cell Transplantation.
Authors: Anne Klink, Christoph Kasper, Sebastian Scholl, Lars-Olof Muegge, Kristina Schilling, Anja Markusch, Klaus Hoeffken, Herbert G. Sayer
Journal: Blood (2004)
Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma.
Authors: Andrew J. Mungall, Andy Chu, Readman Chiu, Richard Corbett, Matthew A. Field, Shaun D. Jackman, Karen L. Mungall, Kim Wong, Merrill Boyle, Rebecca Carlsen, Susanna Y. Chan, Robin J.N. Coope, Carrie A. Hirst, Martin Hirst, Nathalie Johnson, Martin Krzywinski, Darlene Lee, Jasmine BingXue Lin, Richard Moore, Tesa Severson, Jared T. Simpson, Christian Steidl, Thomas Zeng, Yongjun Zhao, Inanc Birol, Robert A. Holt, Steven J. Jones, Randy D. Gascoyne, Douglas E. Horsman, Joseph M. Connors, Jacqueline E. Schein, Marco A. Marra
Journal: Blood (2009)
Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Authors: John M. Burke, Richard H. Van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Richard E. White, Mihaela C. Munteanu, Regina Clementi, Ling Chen, Ian W. Flinn
Journal: Blood (2012)
Association of CD33 Expression Level with Disease Risk-Group Classification and Induction Response In Pediatric AML: A Report From the Children's Oncology Group
Authors: Jessica A. Pollard, Todd A. Alonzo, Robert B. Gerbing, Phoenix A. Ho, Rhonda Ries, Rong Zeng, Kristen L. Miller, Julia Kuhn, Susana C. Raimondi, Betsy A. Hirsch, Janet Franklin, Alan S. Gamis, Michael R. Loken, Soheil Meshinchi
Journal: Blood (2010)
Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity
Authors: Shaji K. Kumar, Betsy R. LaPlant, Wee Joo Chng, Jeffrey A. Zonder, Natalie Callander, Vivek Roy, Briant Furth, Charles Erlichman, Keith Stewart
Journal: Blood (2012)
Deletions of Xp22.2 Including PIG-A Locus Lead to Paroxysmal Nocturnal Hemoglobinuria.
Authors: Christine L. O'Keefe, Chiharu Sugimori, Manuel Afable, Michael Clemente, Kenneth Shain, David Araten, Alan F. List, P.K. Epling-Burnette, Jaroslaw Maciejewski
Journal: Blood (2010)
The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors
Authors: Yaser Homsi, Dareen Alwan, Patrick Kiel, Lindsay Rosenbeck, Srivastava Shivani, Jennifer E. Schwartz, Robert P. Nelson, Rafat Abonour, Michael Robertson, Sherif Farag
Journal: Blood (2010)
Association of Increased Ring Ssideroblasts with Inferior Survival in Patients with Myelodysplastic Syndrome with Multi-Lineage Dysplasia
Authors: Hiroshi Kawabata, Kaoru Tohyama, Akira Matsuda, Kayano Araseki, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano, Kei Shinbo, Kensuke Usuki, Akira Hangaishi, Shigeru Chiba, Nogawa Masaharu, Nobuyoshi Arima, Takayuki Ishikawa, Keiya Ozawa, Shunya Arai, Mineo Kurokawa, Akifumi Takaori-Kondo
Journal: Blood (2016)
Neither the Response of Committed Progenitors to Growth Factors nor the Detection of Apoptosis in Bone Marrow Cells Can Predict the Clinical Response to Treatment in Patients with Rars.
Authors: Alexandra Kouraklis, Argiris Symeonidis, Eleni Thanopoulou, Panagiota Tsoplou, Anastasia Galani, Nicolas Zoumbos
Journal: Blood (2004)
Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia
Authors: Hao Jiang, Daihong Liu, Lanping Xu, Kaiyan Liu, Shanshan Chen, Bin Jiang, Qian Jiang, Huan Chen, Yuhong Chen, Wei Han, Xiaohui Zhang, Yazhen Qin, Yueyun Lai, Yanrong Liu, Xiaojun Huang
Journal: Blood (2013)
Effects of the Second Generation Tyrosin Kinase Inhibitors on Osteogenic Differentiation.
Authors: Daniele Tibullo, Ignazio Barbagallo, Cesarina Giallongo, Piera La Cava, Antonio Branca, Concetta Conticello, Fabio Stagno, Annalisa Chiarenza, Giuseppe A Palumbo, Francesco Di Raimondo
Journal: Blood (2010)
Christian doctor who refused to use preferred pronouns loses employment tribunal case
Authors: Clare Dyer
Journal: BMJ (2019)

A Christian doctor who claimed that he was forced out of his job as a disability assessor for the Department for Work and Pensions because he refused to address transgender claimants by their preferred pronouns and titles has lost his case at an employment tribunal.1

David Mackereth, 56, claimed that he had been discriminated against and denied the right to freedom of thought, conscience, and religion after he insisted on using the pronouns and titles appropriate to a person’s biological sex. This contravened the DWP’s agreed practice of using the pronouns and titles preferred by the individual.

Mackereth told the Birmingham employment tribunal that he believed in the truth of the Bible, including the words in …
Long-Term Outcome of Six Months Maintenance Chemotherapy for ALL in Children: An Extended Follow up Study of TCCSG L92-13
Authors: Motohiro Kato, Atsushi Manabe, Sae Ishimaru, Daisuke Tomizawa, Daisuke Hasegawa, Takeshi Inukai, Yuki Arakawa, Takahiro Aoki, Mayuko Okuya, Kiyohiko Kaizu, Keisuke Kato, Yuichi Taneyama, Katsuyoshi Koh, Masahiro Tsuchida, Akira Ohara
Journal: Blood (2014)
Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate
Authors: Arlene Dawravoo, Reem Karmali, Amy Rizman, Stephanie A. Gregory, Melissa L Larson, Parameswaran Venugopal, Jamile M. Shammo
Journal: Blood (2010)
New trial of convection enhanced drug delivery (CED) in DIPG- applying the SIOPe DIPG survival prediction model for power calculation.
Authors: Elwira Szychot, Peter Collins, Hannah Cassidy, Mohammed Desai, Harpreet Hyare, Ananth Shankar, Steven Gill, Dannis van Vuurden, Sophie Veldhuijzen van Zanten, David Walker
Journal: Neuro-Oncology (2019)

Abstract Background In diffuse intrinsic pontine glioma (DIPG) drug resistance is in part due to inadequate penetration of blood-brain barrier (BBB) by systemically administered drugs. Convection-enhanced drug delivery (CED) techniques have been established to bypass BBB. Trial design to measure efficacy requires evidence to justify power calculation. Aims To apply SIOPe DIPG registry survival prediction tool to pilot cohort of children with DIPG treated with CED of carboplatin and sodium valproate. Methods Case note and imaging review of 9 children with typical DIPG on imaging who were treated on compassionate basis with CED intra-tumoural infusions of carboplatin (0.12 mg/ml) and sodium valproate (14.4 mg/ml), after radiotherapy (n=9) and chemotherapy (n=4). Each had Renishaw device placed with 4 micro-catheters located within tumour mass. Up to 8 treatment cycles of CED infusions delivered through 2 pairs of catheters on 2 days to encompass pontine tumour volume. Survival prediction was performed using clinical criteria: age, sex, duration of symptoms, prior chemotherapy; and radiological criteria: absence of distant metastases; disease involving more than 50% of, and confined to, pons, ring enhancement at diagnosis. Results Cases were categorized as intermediate or high-risk using SIOPe risk scoring with predicted median overall survival (OS) of 9.7, and 7.0 months, respectively. Four patients, categorized as high-risk, had median overall survival (OS) of 14.2 months. Five children, categorized as standard-risk, had median OS of 16.0 months. Conclusions Results justify a phase 2 trial of CED carboplatin and sodium valproate powered to detect at least 4-month prolongation of survival.
Impact of donor, recipient and matching on survival after high emergency lung transplantation in France
Authors: Arnaud Roussel, Edouard Sage, Gilbert Massard, Pascal-Alexandre Thomas, Yves Castier, Elie Fadel, Françoise Le Pimpec-Barthes, Jean-Michel Maury, Jacques Jougon, Philippe Lacoste, Johanna Claustre, Marcel Dahan, Augustin Pirvu, Adrien Tissot, Matthieu Thumerel, Gabrielle Drevet, Ciprian Pricopi, Jérôme Le Pavec, Hervé Mal, Xavier-Benoit D'Journo, Romain Kessler, Antoine Roux, Richard Dorent, Gabriel Thabut, Pierre Mordant
Journal: European Respiratory Journal (2019)

Since July 2007, the French high emergency lung transplantation (HELT) allocation procedure prioritises available lung grafts to waiting patients with imminent risk of death. The relative impacts of donor, recipient and matching on the outcome following HELT remain unknown. We aimed at deciphering the relative impacts of donor, recipient and matching on the outcome following HELT in an exhaustive administrative database.All lung transplantations performed in France were prospectively registered in an administrative database. We retrospectively reviewed the procedures performed between July 2007 and December 2015, and analysed the impact of donor, recipient and matching on overall survival after the HELT procedure by fitting marginal Cox models.During the study period, 2335 patients underwent lung transplantation in 11 French centres. After exclusion of patients with chronic obstructive pulmonary disease/emphysema, 1544 patients were included: 503 HELT and 1041 standard lung transplantation allocations. HELT was associated with a hazard ratio for death of 1.41 (95% CI 1.22-1.64; p<0.0001) in univariate analysis, decreasing to 1.32 (95% CI 1.10-1.60) after inclusion of recipient characteristics in a multivariate model. A donor score computed to predict long-term survival was significantly different between the HELT and standard lung transplantation groups (p=0.014). However, the addition of donor characteristics to recipient characteristics in the multivariate model did not change the hazard ratio associated with HELT.This exhaustive French national study suggests that HELT is associated with an adverse outcome compared with regular allocation. This adverse outcome is mainly related to the severity status of the recipients rather than donor or matching characteristics.
The Evaluation of Clinical and Molecular Response to High-Dose Chemotherapy Protocol NHL BFM-90 in Adults with Anaplastic Large Cell ALK-Positive Lymphoma
Authors: Liliya Gorenkova, Sergey K Kravchenko, Yulia Vinogradova, Ekaterina Ilyushkina, Andrey Misurin, Valeryi G Savchenko
Journal: Blood (2011)
Rituximab-Mediated Inhibition of the p38 MAPK and NF-κB Survival Pathways In Vitro and Validation in Nude Mice Bearing the Raji B-NHL Tumor.
Authors: Mario I. Vega, Sara Huerta-Yepez, Melisa A. Martinez-Paniagua, Cesar G. Bonilla, Benjamin Bonavida
Journal: Blood (2006)
Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.
Authors: Eric Jourdan, Jean-Michel Boiron, Nicole Dastugue, Norbert Vey, Gérald Marit, Françoise Rigal-Huguet, Lysiane Molina, Nathalie Fegueux, Arnaud Pigneux, Christian Recher, Jean-François Rossi, Michel Attal, Jean-Jacques Sotto, Dominique Maraninchi, Josy Reiffers, Valérie-Jeanne Bardou, Didier Blaise
Journal: Blood (2004)
Waist Circumference and Risk of Liver Cancer: A Systematic Review and Meta-Analysis of over 2 Million Cohort Study Participants
Authors: Jamal Rahmani, Hamed Kord Varkaneh, Vasileios  Kontogiannis, Paul M. Ryan, Hiba Bawadi, Somaye Fatahi, Yong Zhang
Journal: Liver Cancer (2019)

&lt;b&gt;&lt;i&gt;Purpose:&lt;/i&gt;&lt;/b&gt; Liver cancer is the sixth most common type of cancer worldwide, and waist circumference (WC) is associated with its risk beyond body mass index (BMI). This dose-response meta-analysis was performed to investigate the association between WC and the risk of incident liver cancer using prospective cohort studies. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A comprehensive systematic search was conducted in MEDLINE/PubMed, Web of Science databases, Scopus, and Coch­rane from inception to May 2019. Studies with retrospective or prospective cohort design that reported hazard ratio (HR), risk ratio, or odds ratio, and the corresponding 95% confidence intervals (CI) for liver cancer based on WC categories were included in this meta-analysis. Combined HRs with 95% CIs was estimated by DerSimonian and Laird random-effects models. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Associations between WC and liver cancer were reported in 5 articles with 2,547,188 participants. All studies were published between 2013 and 2019. Pooled results showed a strong significant association with minimum heterogeneity between WC and risk of liver cancer (HR 1.59, 95% CI 1.38–1.83, &lt;i&gt;p&lt;/i&gt;&lt;sub&gt;heterogeneity&lt;/sub&gt; = 0.42: &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 0%). Moreover, a dose-response model indicated a significant positive association between WC and risk of liver cancer (exp(b) = 1.018, &lt;i&gt;p&lt;/i&gt; &amp;#x3c; 0.001). &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; This systematic review and dose-response meta-analysis highlights WC as a significant risk factor related to the incidence of liver cancer.
Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).
Authors: David S. Siegel, A. Krishnan, S. Lonial, G. Chatta, M. Alsina, S. Jagannath, P. Richardson, R.J. Hohl, J.A. Lust, W. Bensinger, G. Carrum, J. Moreb, A. Simic, B. Barlogie, R.T. Maziarz, K.C. Anderson, J. Lin, A. Lowe, S. Vetticaden, J. Zhu
Journal: Blood (2006)
Leukemia during Pregnancy: 32 Cases from a Single Institution.
Authors: Ayman Alhejazi, Mahmoud Aljurf, Entezam Sahovic, Fahed Almhareb, Irfan Maghfoor, Fahad Alsharif, Hazzaa Alzahrani, Hamad Alomar, Ali Alshanqeeti, Amal Albeihani, Syed Zaidi, Naeem Chaudhri
Journal: Blood (2004)
Blocking VIP Signaling during Allogeneic Bone Marrow Transplantation Separates the Graft Versus Leukemia from Graft Versus Host Disease Activity of Donor CD8 T-Cells
Authors: Jian-Ming Li, Christopher T Petersen, Jingxia Li, Cynthia R. Giver, Bruce R. Blazar, Edmund K Waller
Journal: Blood (2015)
Telomere Elongation in Dyskeratosis Congenita Induced Pluripotent Stem Cells.
Authors: Suneet Agarwal, Yuin-Han Loh, Erin M McLoughlin, Junjiu Huang, In-Hyun Park, Justine D Miller, Hongguang Huo, Maja Okuka, Rosana Maria dos Reis, Sabine Loewer, David Keefe, Frederick D Goldman, Aloysius Klingelhutz, Lin Liu, George Q. Daley
Journal: Blood (2009)
Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.
Authors: Francesco Passamonti, Elisabetta Gattoni, Francisco Cervantes, Heinz Gisslinger, Ronald Paquette, Robert P Gale, Srdan Verstovsek, Ayalew Tefferi
Journal: Blood (2009)
Polymorphism in the IFN-γ Gene Is Associated with Severe Acute Graft Versus Host Disease in β Thalassemia Major Patients Undergoing Matched Related Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Shanmugaapriya Sellathamby, Ryad Tamouza, Kavitha M. Lakshmi, Vikram Mathews, Auro Viswabandhya, Biju George, Mammen Chandy, Rajagopal Krishnamoorthy, Dominique Charron, Alok Srivastava
Journal: Blood (2007)
Cognitive Effects of Once Weekly (QW) Epoetin Alfa in Anemic Patients (pts) with Hematologic Malignancies Receiving Chemotherapy (CT): Interim Results of the EPOLYM Trial.
Authors: Christian Gisselbrecht, Hans Tesch, Eric Jourdan, Giuseppe Avvisati, Costas Tsatalas, Norbert Marschner
Journal: Blood (2004)
Neutrophils Of Multiple Myeloma Are Dysfunctional and Immunosuppressive
Authors: Nunziatina Parrinello, Alessandra Romano, Concetta Conticello, Maide Cavalli, Alessia La Fauci, Giuseppina Rizzo, Piera La Cava, Annalisa Chiarenza, Daniele Tibullo, Cesarina Giallongo, Giuseppe A Palumbo, Francesco Di Raimondo
Journal: Blood (2013)
Risk-Adapted, MRD-Refined Therapeutic Approach for the Treatment of Acute Myeloid Leukemia: From a Single Center Experience to the Cooperative Gimema Protocol AML1310
Authors: Adriano Venditti, Francesco Buccisano, Luca Maurillo, Maria Ilaria Del Principe, Paola Fazi, Marco Vignetti, Francesco Lo Coco, William Arcese, Sergio Amadori
Journal: Blood (2012)
Real-World Effectiveness of Nivolumab by PD-L1 Expression in NSCLC pts in Japan: A Multicenter-Retrospective Study
Authors: Young Hak Kim, Ryo Morita, Kyoichi Okishio, Junichi Simizu, Haruhiro Saito, Hiroshi Sakai, Osamu Hataji, Makiko Yomota, Makoto Nishio, Keisuke Aoe, Osamu Kanai, Toru Kumagai, Kayoko Kibata, Hiroaki Tsukamoto, Satoshi Oizumi, Keisuke Tomii, Hiroshi Tanaka, Keiko Mizuno, Hirotoshi Hoshiyama, Kenya Ochi, Yuichiro Ohe
Journal: Annals of Oncology (2019)
Anti-Myeloma Activity of Modified Galectin-9 through JNK and p38 MAPK Pathways.
Authors: Tsutomu Kobayashi, Junya Kuroda, Eishi Ashihara, Yasuhito Terui, Souichi Oomizu, Mio Yamamoto, Akiko Taniyama, Yosuke Matsumoto, Shigeo Horiike, Kiyohiko Hatake, Akira Yamauchi, Mitsuomi Hirashima, Masafumi Taniwaki
Journal: Blood (2009)
Blockade of B7H1 by Monoclonal Antibodies Enhances Therapeutic Immunity of DKK1 Vaccine in Multiple Myeloma
Authors: Jianfei Qian, Yuhuan Zheng, Lijuan Wang, Sungyoul Hong, Haiyan Li, Yong Lu, Jin He, Jing Yang, Larry W Kwak, Qing Yi
Journal: Blood (2011)
Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.
Authors: Maurizio Di Liberto, Xiangao Huang, Rediet Zewdu, Francesco Parlati, Monette Aujay, Ruben Niesvizky, Selina Chen-Kiang
Journal: Blood (2009)
Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT)
Authors: Elena Buces, Carolina Martínez-Laperche, Milagros González-Rivera, Anna Bosch-Vizcaya, Beatriz Martin-Antonio, Vicent Guillem, Jose B Nieto, Marcos González, Rafael De La Camara, Salut Brunet, Antonio Jimenez-Velasco, Ildefonso Espigado, Carlos Vallejo, Antonia Sampol, Jose Maria Bellon, David Serrano, Mi Kwon, Jorge Gayoso, Balsalobre Pascual, Alvaro Urbano-Izpizua, Carlos Solano, David Gallardo, José Luis Díez Martín, Ismael Buno
Journal: Blood (2014)
Long-term results of a PII study of chemoradiotherapy with docetaxel, nedaplatin, and fluorouracil for esophageal cancer
Authors: Hiroyuki Ohnuma, Naoki Onoyama, Naotaka Hayasaka, Masanori Sato, Kazuyuki Murase, Koichi Takada, Koji Miyanishi, Masahiro Hirakawa, Tamotsu Sagawa, Masakazu Hori, Masanori Someya, Kensei Nakata, Koichi Sakata, Junji Kato
Journal: Annals of Oncology (2019)
Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
Authors: Ramon Garcia-Sanz, Anna Sureda, Sara Alonso-Alvarez, Ana Pilar Gonzalez, Antonia Rodriguez, Antonio Salar, Fatima de la Cruz, Eva Domingo, Miriam Moreno, Javier Lopez, Jose Luis Piñana, Gabriela Rodriguez, Miguel Canales, Antonio Manuel Gurierrez, Armando López-Guillermo, María Dolores Caballero, Silvia Jimenez, Carmen Martinez
Journal: Blood (2015)
ESAM Is a Novel Human Hematopoietic Stem Cell Marker Associated with a Subset of Human Leukemias
Authors: Tomohiko Ishibashi, Takafumi Yokota, Hirokazu Tanaka, Michiko Ichii, Takao Sudo, Yusuke Satoh, Yukiko Doi, Akira Tanimura, Yuri Hamanaka, Sachiko Ezoe, Hirohiko Shibayama, Kenji Oritani, Yuzuru Kanakura
Journal: Blood (2015)
Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes
Authors: Zohra Nooruddin, Zenggang Pan, Lilyana Gross, Weitzenkamp David, Bradley M. Haverkos, Daniel A Pollyea, Jonathan A Gutman, William Robinson, Clayton Smith, Jeffrey Schowinsky, Purev Enkhtsetseg, Daniel W. Sherbenou, Rachel Rabinovitch, Douglas Ney, Craig T Jordan, Manali Kamdar
Journal: Blood (2016)
Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.
Authors: Michael P Osborn, Deborah L White, Verity A Saunders, Bronwyn Cambareri, Susan Branford, Andrew Menelaou, Bereha Khodr, Cassandra Slader, Mark Hertzberg, Anthony Schwarer, David Ma, Christopher Arthur, Cecily J. Forsyth, Samar Issa, Yiu Lam Kwan, John Taper, Andrew Grigg, Timothy P. Hughes
Journal: Blood (2009)
The Role of Human Nucleoside Transporters In Uptake of 5-Azacitidine, 5-Aza-2′-Deoxycytidine and Gemcitabine
Authors: Zeen Tong, Vijaya Damaraju, Sylvia Yao, Amy Ng, James Young, Carol Cass, Sekhar Surapaneni, Gondi Kumar
Journal: Blood (2010)
Focal Adhesion Kinase Regulates Critical Functions in Hematopoiesis.
Authors: Sasidhar Vemula, Benjamin P. Abratigue, Premchand Gandra, John T. O’Malley, Ayek-Nati N. Ahyi, Gretta Stritesky, Norman Yeh, Mark Kaplan, Hillary Beggs, Reuben Kapur
Journal: Blood (2007)
The Use Of Rituximab For Preventing Delayed Haemolytic Transfusion Reaction In Highly Immunized Patients With Sickle Cell Disease
Authors: France Noizat-Pirenne, Marc Michel, Armand Mekontso-Dessap, Constance Guillaud, Keyvan Razazi, Matthieu Mahévas, Sadaf Pakdaman, Frederic Galacteros, Pablo Bartolucci, Anoosha Habibi
Journal: Blood (2013)
Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabtheraâ) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma : A Phase III Randomized Intergroup Clinical Trial.
Authors: Marinus H.J. Van Oers, Martine Van Glabbeke, Ivana Teodorovic, Cynthia Rozewicz, Richard Klasa, Robert E. Marcus, Max Wolf, Eva Kimby, Anton Hagenbeek
Journal: Blood (2004)
A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib
Authors: James R. Berenson, Jacob D. Bitran, Imad Tabbara, Jose Lutzky, Laura V. Stampleman, Sikander Ailawadhi, Ronald Steis, Mehdi M. Moezi
Journal: Blood (2014)
Tumor Suppressors BTG1 and IKZF1 Cooperate during Mouse Leukemia Development and Impact Relapse Rate in Childhood Acute Lymphoblastic Leukemia
Authors: Blanca Scheijen, Esther Tijchon, Dorette van Ingen Schenau, Rene Marke, Liesbeth van Emst, Laurens T Van Der Meer, Roland P Kuiper, Judith M. Boer, Rob Pieters, Peter M Hoogerbrugge, Monique L. Den Boer, Frank N van Leeuwen
Journal: Blood (2015)
Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models
Authors: Saar Gill, Sarah K Tasian, Marco Ruella, Olga Shestova, Yong Li, David L. Porter, Martin Carroll, Gwenn Danet-Desnoyers, John Scholler, Stephan A Grupp, Carl H. June, Michael Kalos
Journal: Blood (2013)